PHARMExcel named among the best CRO specialist providers

PHARMExcel, a leading UK-based Contract Research Organisation (CRO) specialising in high-quality clinical trial management, proudly announces its recognition in the “Best Contract Research Organisation – Specialist Providers” category at the prestigious 2024 SCRIP Awards. This honour highlights PHARMExcel’s commitment to delivering exceptional services in clinical research, underpinned by a steadfast dedication to quality, innovation, and patient-centric approaches.

The accolade comes during a milestone year for PHARMExcel as it celebrates 15 years of driving excellence in clinical research. Known for its bespoke, quality-driven services, the company has consistently exceeded client expectations through its personalised client-facing approach and clinical delivery expertise.

“This recognition at the SCRIP Awards is a testament to the passion and expertise of our talented team,” said Yvanne Enever, CEO and Founder of PHARMExcel. “We are deeply committed to advancing clinical research through strategic partnerships and a relentless focus on quality. It’s an honour to see our efforts acknowledged on such a prestigious global platform.”

Margaret Irwin, PHARMExcel’s Head of Clinical Operations, added:
“Our success is driven by our people and their dedication to delivering excellence in clinical trials. At PHARMExcel, we pride ourselves on fostering strong relationships with our clients and sites, ensuring every study we manage is of the highest quality and integrity. This recognition underscores the difference a collaborative and quality-focused approach can make.”

The annual SCRIP Awards, hosted by Citeline, celebrates outstanding achievements in global biopharma, recognizing key innovations that shape the healthcare industry. Winners are selected by an esteemed panel of life sciences executives, and the “Best CRO – Specialist Providers” category acknowledges the critical contributions of CROs in supporting groundbreaking drug development. PHARMExcel’s recognition reflects its excellence in clinical trial delivery, patient engagement, and regulatory compliance.

The award reinforces PHARMExcel’s position as a trusted partner for biotech, pharmaceutical, and medical device companies seeking tailored clinical research solutions. With a focus on fostering collaboration, embracing innovation, and maintaining the highest standards of compliance, PHARMExcel remains committed to transforming healthcare and improving patient outcomes.

Congratulations to all the other CROS who took part in the SCRIP awards.

• PHARMExcel
• CTI Clinical Trial & Consulting Services
• Fortrea
• ICON
• Novotech
• Parexel
• Tigermed
• Allucent
• Bioforum
• Cellomatics Biosciences
• Cerba Research
• Crown Bioscience
• OWL Oncology Research
• Phastar

• To ensure alignment with the company’s core values and ethical standards, PHARMExcel appointed a Head of People & Culture in 2024 to lead the EDI strategy. By embedding EDI principles into its organisational culture, PHARMExcel not only enhances employee engagement and innovation but also improves the quality and inclusiveness of its clinical research processes.

• PHARMExcel adopts patient-centred clinical trial design. It supports patient-public initiatives such as those driven by rare disease patient advocacy groups the MPS Society and the Rare Disease Research Partners to address shortfalls in, and improve delivery and impact of, clinical research. Part of this initiative is to look at the challenges and opportunities for effective partnerships between patients, relatives, clinicians (including trainees), research staff and academics.

• PHARMExcel understands the importance of feasibility and site selection in promoting inclusion and diversity and encourages its sponsors to select sites with the best representation across patient groups.

• Where possible PHARMExcel reduces the need for patients to travel to sites and operates remote trial monitoring.

• PHARMExcel will regularly monitor recruitment data to identify and address disparities in enrolment.

• PHARMExcel continues to support its landlord’s environmental and sustainable practices through its Net Zero commitment achieving 34% carbon emissions reduction from 2019-2023.

• PHARMExcel adopts a recycling and clean energy progamme.

• Its solar generation equivalent carbon savings is 708 tonnes to date.

• PHARMExcel is committed to supporting local and national community initiatives such as food banks and charities including Alzheimer’s Research.

About PHARMExcel

PHARMExcel is an award-winning, full-service Contract Research Organisation (CRO) providing a flexible and innovative approach to clinical trial delivery. The company is recognised for its in-depth knowledge and experience of the clinical research environment, particularly in the UK, and has a network of regulatory and industry associates, allowing it to provide a global reach.

Media Contact
Katie Howe, Head of  Marketing
E: katie.howe@pharmexcel-cro.com
T: +44 (0)20 3642 6654